Publications
Detailed Information
Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: A multicenter phase II study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sun Young | - |
dc.contributor.author | Hong, Yong Sang | - |
dc.contributor.author | Kim, Dae Yong | - |
dc.contributor.author | Kim, Tae Won | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Im, Seok Ah | - |
dc.contributor.author | Lee, Keun Seok | - |
dc.contributor.author | Yun, Tak | - |
dc.contributor.author | Jeong, Seung-Yong | - |
dc.contributor.author | Choi, Hyo Seong | - |
dc.contributor.author | Lim, Seok-Byung | - |
dc.contributor.author | Chang, Hee Jin | - |
dc.contributor.author | Jung, Kyung Hae | - |
dc.date.accessioned | 2022-03-22T09:10:55Z | - |
dc.date.available | 2022-03-22T09:10:55Z | - |
dc.date.created | 2021-10-20 | - |
dc.date.created | 2021-10-20 | - |
dc.date.issued | 2011-11 | - |
dc.identifier.citation | International Journal of Radiation Oncology Biology Physics, Vol.81 No.3, pp.677-683 | - |
dc.identifier.issn | 0360-3016 | - |
dc.identifier.other | 144981 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177212 | - |
dc.description.abstract | Purpose: To evaluate the efficacy and safety of preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with rectal cancer. Methods and Materials: Forty patients with locally advanced, nonmetastatic, and mid- to lower rectal cancer were enrolled. Radiotherapy was delivered at a dose of 50.4 Gy/28 fractions. Concurrent chemotherapy consisted of an initial dose of cetuximab of 400 mg/m(2) 1 week before radiotherapy, and then cetuximab 250 mg/m(2)/week, irinotecan 40 mg/m(2)/week for 5 consecutive weeks and capecitabine 1,650 mg/m(2)/day for 5 days a week (weekdays only) from the first day during radiotherapy. Total mesorectal excision was performed within 6 +/- 2 weeks. The pathologic responses and survival outcomes were evaluated as study endpoints, and an additional KRAS mutation analysis was performed. Results: In total, 39 patients completed their planned preoperative chemoradiation and underwent R0 resection. The pathologic complete response rate was 23.1% (9/39), and 3 patients (7.7%) showed near total regression of tumor. The 3-year disease-free and overall survival rates were 80.0% and 94.7%, respectively. Grade 3/4 toxicities included leukopenia (4, 10.3%), neutropenia (2, 5.1%), anemia (1, 2.6%), diarrhea (2, 5.1%), fatigue (1, 2.6%), skin rash (1, 2.6%), and ileus (1, 2.6%). KRAS mutations were found in 5(13.2%) of 38 patients who had available tissue for testing. Clinical outcomes were not significantly correlated with KRAS mutation status. Conclusions: Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine was active and well tolerated. KRAS mutation status was not a predictive factor for pathologic response in this study. (C) 2011 Elsevier Inc. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: A multicenter phase II study | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1016/j.ijrobp.2010.06.035 | - |
dc.citation.journaltitle | International Journal of Radiation Oncology Biology Physics | - |
dc.identifier.wosid | 000296115500010 | - |
dc.identifier.scopusid | 2-s2.0-80053591096 | - |
dc.citation.endpage | 683 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 677 | - |
dc.citation.volume | 81 | - |
dc.identifier.sci | 000296115500010 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Im, Seok Ah | - |
dc.contributor.affiliatedAuthor | Jeong, Seung-Yong | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | METASTATIC COLORECTAL-CANCER | - |
dc.subject.keywordPlus | RADIATION-THERAPY | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | CHEMORADIOTHERAPY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | RADIOCHEMOTHERAPY | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.subject.keywordAuthor | Cetuximab | - |
dc.subject.keywordAuthor | Capecitabine | - |
dc.subject.keywordAuthor | Irinotecan | - |
dc.subject.keywordAuthor | Preoperative chemoradiotherapy | - |
dc.subject.keywordAuthor | Rectal cancer | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.